Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study aimed to evaluate the effect of vitamin D (VD) supplementation on the pathological complete response (pCR) rate in women with breast cancer (BC) undergoing neoadjuvant chemotherapy (NCT).

Why It Was Studied

A randomized clinical trial was conducted with 80 women aged ≥45years with BC who were eligible for NCT.

The primary outcome measure was the pCR rate.

Who Took Part

The abstract describes 80 women taking part.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Serum 25-hydroxyvitamin-D [25(OH)D] levels were measured after BC diagnosis and the end of NCT.

What Was Measured

The primary outcome measure was the pCR rate.

The subject headings attached to it are Breast Neoplasms, Neoadjuvant Therapy, Vitamin D, Dietary Supplements, Cholecalciferol and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 80 women.

The publication is from 2025 (Nutrition and cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.